Strategikon Pharma
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
AstraZeneca, in alliance with Saint Luke’s Mid America Heart Institute, has started a Phase III clinical trial of its diabetes drug Farxiga (dapagliflozin) to treat hospitalised Covid-19 patients at risk of serious complications.
Farxiga is an oral, once-daily sodium-glucose transport protein 2 (SGLT2) inhibitor indicated for adults with insufficiently controlled type 2 diabetes (T2D), as an adjunct to diet and exercise.
The new randomised, global trial, named DARE-19, will evaluate the drug’s ability to reduce the risk of disease progression, clinical complications, and death from Covid-19 in patients with CV, metabolic or kidney risk factors.
Analysis Budgeting, Forecasting, and Outsourcing Solutions for Clinical Trials
Drug Delivery Development for Advanced Oral Formulations
Digital Solutions for Medical Adherence and Patient Retention